Cathy Swindlehurst, PHD

Cathy A. Swindlehurst, Ph.D. (President and CEO) has over 30 years of experience in the biotechnology industry and has been the President and CEO of NovoMedix since its inception in 2001. Dr. Swindlehurst has a broad background in assay and biomarker development; drug discovery and development; as well as in project management, business development, and fund raising. Dr. Swindlehurst has held V.P. positions at several companies, including PanCel, MagneSensors, and NovaDx (which she co-founded, and where she developed a novel biomarker assay currently marketed by Quidel for arthritis and breast cancer). She has led key collaborations with academic researchers and corporate partners and has been directly involved in raising over $10M in financing. Dr. Swindlehurst is an inventor on NovoMedix’s key issued patents. In her role as CEO of NovoMedix, Dr. Swindlehurst has also raised $6M, mostly in the form of non-dilutive funding.